Valneva Se · EURONEXT:VLA
Valneva — Shareholder Meeting (June 2024)
83 slides from Valneva's shareholder meeting presentation, Jun 26, 2024
Slide 1: 2023 Combined General Meeting
2023 Combined General Meeting June 26, 2024 Lyon
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an Certain information and statements included in this presentation are not historical offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any facts but are forward-looking sta
Slide 3: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 4: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 5: Preliminary Formalities
Preliminary Formalities Sign attendance sheet (All) Appoint AGM committee (Chair, Observers, Secretary) Validation of the Quorum (Secretary) Documents filed with the AGM committee (Secretary) Agenda (Chairperson) Valneva Combined General Meeting - June 26, 2024
Slide 6: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 7: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 8: A Leading Specialty Vaccine Company
A Leading Specialty Vaccine Company Focused on vaccines that make a difference We develop, manufacture, & commercialize prophylactic vaccines for infectious diseases addressing unmet medical needs 2023 has been a major year for Valneva, with notably: o The U.S. approval of IXCHIQ®, the world‘s fir
Slide 9: Valneva's Commercial and R&D Portfolio
Valneva’s Commercial and R&D Portfolio Further extending a unique, best-in class portfolio Program Vaccine Design Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial IXIARO® Only U.S./ EU approved vaccine against Japanese encephalitis Commercial DUKORAL® Established Cholera (ETEC*) vaccine approved in >
Slide 10: Our Strategy to become a Globally Recognized Vaccine Company
Our Strategy to become a Globally Recognized Vaccine Company Contribute to a world where no one dies or suffers from a vaccine preventable disease Drive Maximize Commercial Capture integrated Growth R&D Upside biotech model Unlock IXCHIQ® value by building Invest in new vaccines that address B
Slide 11: IXCHIQ: The World's First and Only Licensed Chikungunya Vaccine
IXCHIQ®: The World’s First and Only Licensed Chikungunya Vaccine FDA-approved in adults, with potential additional regulatory approvals in 2024 Vaccine Highlights Market Opportunity Upcoming Milestones • Live-attenuated: offers strong and long- • Travelers • Potential upcoming approvals: EMA, lastin
Slide 12: VLA15: World's Leading Vaccine Candidate Against Lyme Disease
VLA15: World’s leading Vaccine Candidate Against Lyme Disease The only Lyme disease program in advanced clinical development today Vaccine Highlights Market Opportunity Upcoming Milestones • Multivalent, recombinant proteins • Exclusive, worldwide partnership1 • Complete Valneva contribution to Phas
Slide 13: VLA1601: Optimized Second-Generation Vaccine Candidate Against Zika Virus
VLA1601: Optimized Second-Generation Vaccine Candidate Against Zika Virus Entering Phase 1, further program evaluation planned Vaccine Highlights Market Opportunity Upcoming Milestones • Second-generation adjuvanted • Flaviviral disease transmitted by Aedes • Execute Phase 1 clinical trial with enha
Slide 14: Key Upcoming Catalysts and News Flow in 2024
Key Upcoming Catalysts and News Flow in 2024 Chikungunya vaccine Upcoming potential approvals: EMA, Anvisa (Brazil), MHRA (UK) Initiate Phase 3 immunocompromised individuals study in H1 2024 File for potential label extension Initiate Phase 4 clinical program Lyme disease vaccine candidate V
Slide 15: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 16: FY 2023 Financials: Product Sales of €144.6 million
FY 2023 Financials: Product Sales of €144.6 million Commercial business showing continued, significant growth €m (audited) FY FY % % 2023 2022 Change at CER* IXIARO®/JESPECT® 73.5 41.3 +78% +84% DUKORAL® 29.8 17.3 +72% +82% Third party products 35.7 26.5 +34% +37% Total product sales (excl. COVID-19
Slide 17: FY 2023 Financials: Income Statement
FY 2023 Financials: Income Statement €m (unaudited) FY 2023 FY 2022 Product sales 144.6 114.8 Other Revenues 9.1 246.5 Revenues 153.7 361.3 Cost of goods and services (100.9) (324.4) Research and development expenses (59.9) (104.9) Marketing and distribution expenses (48.8) (23.5) General and admini
Slide 18: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 19: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 20: Summary of the Auditors' Reports
Summary of the Auditors’ Reports 2023 Financial statements and authorizations for share capital operations The Statutory Auditors have performed the procedures that they considered necessary in accordance with the professional guidelines of the French National Institute of Statutory Auditors (Compag
Slide 21: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements authorized and executed during the fiscal year 2023 Management Agreement executed between Mr. Franck Grimaud and Valneva SE on December 19, 2023 Nature and purpose : This agreement speci
Slide 22: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements authorized and executed during the fiscal year 2023 Management Agreement executed between Mr. Frédéric Jacotot and Valneva SE on December 19, 2023 Nature and purpose : This agreement spe
Slide 23: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements authorized and executed during the fiscal year 2023 Sale and Purchase Agreement executed between Blink Biomedical SAS et Valneva SE on September 8, 2023 Nature and purpose : The Sale and
Slide 24: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements authorized and executed during the fiscal year 2023 Amended and Restated Agreement executed between Vital Meat SAS and Valneva SE, with effect on June 21, 2023 Nature and purpose : The A
Slide 25: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements authorized and executed during the fiscal year 2023 Directors and Officers indemnification agreement Nature and purpose : Under the terms of the agreements, the Company undertakes – to t
Slide 26: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements already approved by the Annual General Meeting and in place during the fiscal year 2023 Sale and Licensing Agreement executed between Vital Meat SAS and Valneva SE on May 4, 2022 Nature
Slide 27: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements already approved by the Annual General Meeting and in place during the fiscal year 2023 Management Agreement executed between Mr. Franck Grimaud and Valneva SE on March 22, 2022 Nature a
Slide 28: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements already approved by the Annual General Meeting and in place during the fiscal year 2023 Management Agreement executed between Mr. Frédéric Jacotot and Valneva SE on March 22, 2022 Nature
Slide 29: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements already approved by the Annual General Meeting and in place during the fiscal year 2023 Directors and Officers indemnification agreements Nature and purpose : Under the terms of the agre
Slide 30: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements already approved by the Annual General Meeting and in place during the fiscal year 2023 Amendment 4 to the Premises and Equipment Provision Agreement, executed with Vital Meat SAS and ef
Slide 31: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements already approved by the Annual General Meeting and in place during the fiscal year 2023 Amendment 2 & 3 to the Premises and Equipment Provision Agreement with Vital Meat SAS, entered int
Slide 32: Summary of the Auditors' Reports
Summary of the Auditors’ Reports Related party agreements Excerpts from the Statutory Auditors’ report Agreements already approved by the Annual General Meeting and in place during the fiscal year 2023 Premises and Equipment Provision Agreement executed on September 27, 2018 with Groupe Grimaud La C
Slide 33: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 34: Important Note
IMPORTANT NOTE Some of the resolutions shown on the following slides have been summarized. For the full text version, please refer to the “Investors” / “General Meetings” / “June 26, 2024 Combined General Meeting” section of Valneva’s website www.valneva.com. The English resolutions and their Englis
Slide 35: Resolution 1 - Approval of the parent entity financial statements
Resolution 1 - Approval of the parent entity financial statements for the fiscal year ended December 31, 2023 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after having reviewed the parent entity financial statements
Slide 36: Resolution 2 - Approval of the consolidated financial statements
Resolution 2 - Approval of the consolidated financial statements for the fiscal year ended December 31, 2023 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after having reviewed the consolidated financial statements an
Slide 37: Resolution 3 - Appropriation of earnings
Resolution 3 - Appropriation of earnings for the fiscal year ended December 31, 2023 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, resolve to allocate to retained earnings (accumulated deficit) the total loss of sixte
Slide 38: Resolution 4 - Approval of Management Agreements
Resolution 4 - Approval of Management Agreements entered into in the year ended December 31, 2023, pursuant to Articles L. 225-38 et seq. of the French Commercial Code The Shareholders, acting in accordance with the quorum and majority requirements applicable to Ordinary General Meetings, after havi
Slide 39: Resolution 5 - Approval of Blink Biomedical Sale and Purchase Agreement
Resolution 5 - Approval of the Sale and Purchase Agreement entered into between Blink Biomedical SAS and Valneva SE in the year ended December 31, 2023, pursuant to Articles L. 225-38 et seq. of the French Commercial Code The Shareholders, acting in accordance with the quorum and majority requiremen
Slide 40: Resolution 6 - Approval of Vital Meat Amended and Restated Agreement
Resolution 6 - Approval of the Amended and Restated Agreement between Vital Meat SAS and Valneva SE for the year ending December 31, 2023, pursuant to articles L. 225-38 et seq. of the French Commercial Code. The Shareholders, acting in accordance with the quorum and majority requirements applicable
Slide 41: Resolution 7 - Approval of indemnification agreements
Resolution 7 - Approval of indemnification agreements entered into in favor of corporate officers in the year ended December 31, 2023, pursuant to Articles L. 225-38 et seq. of the French Commercial Code. The Shareholders, acting in accordance with the quorum and majority requirements applicable to
Slide 42: Resolution 8 - Appointment of Ms. Danièle Guyot-Caparros as Director
Resolution 8 - Appointment of Ms. Danièle Guyot-Caparros as Director The Shareholders, acting in accordance with the quorum and majority requirements applicable to Ordinary General Meetings, after having reviewed the Board of Directors’ Report, appoint Ms. Danièle Guyot-Caparros as a Director of the
Slide 43: Resolution 9 - Appointment of Deloitte & Associés as Sustainability Auditors
Resolution 9 - Appointment of Deloitte & Associés as Statutory Auditors in charge of certifying sustainability information The Shareholders, acting in accordance with the quorum and majority requirements applicable to Ordinary General Meetings, after having reviewed the Board of Directors’ Report, a
Slide 44: Resolution 10 - Appointment of PricewaterhouseCoopers Audit as Sustainability Auditors
Resolution 10 - Appointment of PricewaterhouseCoopers Audit as Statutory Auditors in charge of certifying sustainability information The Shareholders, acting in accordance with the quorum and majority requirements applicable to Ordinary General Meetings, after having reviewed the Board of Directors’
Slide 45: Resolution 11 - Compensation policy for CEO Thomas Lingelbach
Resolution 11 - Approval of the compensation policy applicable to Mr. Thomas Lingelbach, CEO, for the fiscal year 2024 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Report by the Board of Directo
Slide 46: Resolution 12 - Compensation policy for Franck Grimaud
Resolution 12 - Approval of the compensation policy applicable to Mr. Franck Grimaud, Associate Managing Officer, for the fiscal year 2024 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Report by
Slide 47: Resolution 13 - Compensation policy for Frédéric Jacotot
Resolution 13 - Approval of the compensation policy applicable to Mr. Frédéric Jacotot, Associate Managing Officer, for the fiscal year 2024 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Report b
Slide 48: Resolution 14 - Compensation policy for Juan Carlos Jaramillo
Resolution 14 - Approval of the compensation policy applicable to Mr. Juan Carlos Jaramillo, Associate Managing Officer, for the fiscal year 2024 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Rep
Slide 49: Resolution 15 - Compensation policy for Peter Bühler
Resolution 15 - Approval of the compensation policy applicable to Mr. Peter Bühler, Associate Managing Officer, for the fiscal year 2024 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Report by th
Slide 50: Resolution 16 - Compensation policy for Dipal Patel
Resolution 16 - Approval of the compensation policy applicable to Ms. Dipal Patel, Associate Managing Officer, for the fiscal year 2024 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Report by the
Slide 51: Resolution 17 - Compensation policy for Directors
Resolution 17 - Approval of the compensation policy applicable to the members of the Board of Directors for the fiscal year 2024 The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meetings, after considering the Report by the Board
Slide 52: Resolution 18 - Approval of corporate officer compensation information
Resolution 18 - Approval of the information referred to in Article L. 22-10-9, I of the French Commercial Code, pursuant to Article L. 22-10-34, I of the French Commercial Code The Shareholders, acting in accordance with the quorum and majority voting requirements applicable to Ordinary General Meet
Slide 53: Resolution 19 - 2023 compensation of Anne-Marie Graffin
Resolution 19 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2023, to Ms. Anne-Marie Graffin, Chair of the Board of Directors The Shareholders, acting in a
Slide 54: Resolution 20 - 2023 compensation of Thomas Lingelbach
Resolution 20 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2023, to Mr. Thomas Lingelbach, CEO and former Chair of the Management Board The Shareholders,
Slide 55: Resolution 21 - 2023 compensation of Franck Grimaud
Resolution 21 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2023, to Mr. Franck Grimaud, Associate Managing Officer and former Management Board member The
Slide 56: Resolution 22 - 2023 compensation of Frédéric Jacotot
Resolution 22 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2023, to Mr. Frédéric Jacotot, Associate Managing Officer and former Management Board member T
Slide 57: Resolution 23 - 2023 compensation of Juan Carlos Jaramillo
Resolution 23 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2023, to Mr. Juan Carlos Jaramillo, Associate Managing Officer and former Management Board mem
Slide 58: Resolution 24 - 2023 compensation of Peter Bühler
Resolution 24 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2023, to Mr. Peter Bühler, Associate Managing Officer and former Management Board member The S
Slide 59: Resolution 25 - 2023 compensation of Dipal Patel
Resolution 25 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2023, to Ms. Dipal Patel, Associate Managing Officer and former Management Board member The Sh
Slide 60: Resolution 26 - 2023 compensation of Frédéric Grimaud
Resolution 26 - Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2023, to Mr. Frédéric Grimaud, former Chair of the Supervisory Board The Shareholders, acting
Slide 61: Summary of Resolution 27 - Share buyback authorization
Summary of resolution 27 - Authorization and powers to be given to the Board of Directors for the purpose of allowing the Company to make transactions on its own shares Authorization to the Company, for a period of eighteen (18) months as from this Meeting, in order to: • purchase its own shares up
Slide 62: Resolution 28 - Authorization to cancel treasury shares
Resolution 28 - Authorization granted to the Board of Directors to cancel treasury shares The Shareholders, acting in accordance with the quorum and majority requirements applicable to Extraordinary General Meetings, after having reviewed the Board of Directors’ Report and the Statutory Auditors’ Re
Slide 63: Summary of Resolution 29 - Capital increase with preferential subscription rights
Summary of resolution 29 - Grant of authority to the Board of Directors to increase the share capital by issuing ordinary shares or any securities giving access to the capital, while maintaining the preferential subscription right of the shareholders • Delegation for a period of twenty-six (26) mont
Slide 64: Summary of Resolution 30 - Capital increase by public offering
Summary of resolution 30 - Grant of authority to the Board of Directors to increase the capital by issuing ordinary shares or any securities giving access to the capital through a public offering (other than those referred to in Article L. 411-2, 1° of the French Monetary and Financial Code), cancel
Slide 65: Summary of Resolution 30 - continued
Summary of resolution 30 - continued • Issue price of new shares will be determined by the Board of Directors, under the conditions laid down by law; If no further limit is set by law or regulation, - the issue price for the ordinary shares issued directly will be at least equal to the volume-weight
Slide 66: Summary of Resolution 31 - Capital increase by private placement
Summary of resolution 31 - Grant of authority to the Board of Directors to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company's share capital, with cancellation of preferential subscription rights of the shareholders, through a public
Slide 67: Summary of Resolution 31 - continued
Summary of resolution 31 - continued • Issue price of new shares will be determined by the Board of Directors, under the conditions laid down by law; If no further limit is set by law or regulation, - the issue price for the ordinary shares issued directly will be at least equal to the volume-weight
Slide 68: Summary of Resolution 32 - Setting the issue price
Summary of resolution 32 - Grant of authority to the Board of Directors in the event of an issue of the Company’s ordinary shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders, to set
Slide 69: Summary of Resolution 33 - Capital increase for categories of persons
Summary of resolution 33 - Grant of authority to the Board of Directors to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders for the benefit of
Slide 70: Summary of Resolution 33 - continued
Summary of resolution 33 - continued • Maximal nominal amount of debt securities which may be issued: one hundred forty-three million seven hundred fifty thousand euros (€143,750,000); • Issue price of the shares that may be issued under this delegation be set by the Board of Directors, under the fo
Slide 71: Resolution 34 - Increase in number of shares issued
Resolution 34 - Grant of authority to the Board of Directors to increase the number of shares to be issued in the case of a capital increase, with or without preferential subscription rights for existing shareholders, within the limit of 15% of the initial issue amount The Shareholders, in accordanc
Slide 72: Resolution 35 - Capital increase by capitalization of reserves
Resolution 35 - Grant of authority to the Board of Directors in order to increase the share capital through the capitalization of reserves, earnings or premium The Shareholders, in accordance with the quorum and majority requirements applicable to Ordinary General Meetings, after having reviewed the
Slide 73: Summary of Resolution 36 - Capital increase for contributions in kind
Summary of resolution 36 - Grant of authority to the Board of Directors to increase the share capital by issuing shares and/or securities giving immediate and/or future access to the Company’s share capital, with cancellation of preferential subscription rights of the shareholders, in consideration
Slide 74: Resolution 37 - Maximum aggregate amount of capital increases
Resolution 37 - Maximum aggregate amount of capital increases The Shareholders, in accordance with the quorum and majority requirements applicable to Extraordinary General Meetings, after having reviewed the Board of Directors Report and the Statutory Auditors' Special Report: • resolve that the max
Slide 75: Summary of Resolution 38 - Capital increase reserved for employees
Summary of resolution 38 - Grant of authority to the Board of Directors for the purpose of deciding to carry out a capital increase reserved for employees The Shareholders resolve in accordance with the provisions of article L. 225-129-6 of the French Commercial Code to reserve for the benefit of em
Slide 76: Resolution 39 - Amendment to Article 16.2 of the Articles of Association
Resolution 39 - Amendment to Article 16.2 of the Articles of Association, to delete the reference to the impossibility for Directors to take part in deliberations relating to the approval of accounts by videoconference or other means of telecommunication The Shareholders, acting in accordance with t
Slide 77: Resolution 40 - Amendment to Article 37 of the Articles of Association
Resolution 40 - Amendment to Article 37 of the Articles of Association, entitled "Shareholders' equity less than half the share capital", to bring it into line with statutory provisions The Shareholders, acting in accordance with the quorum and majority requirements applicable to Extraordinary Gener
Slide 78: Resolution 40 - continued
Resolution 40 - continued If, before the deadline referred to in the second paragraph of this article, shareholders' equity has not been reconstituted to a value at least equal to half of the share capital, even though the Company's share capital exceeds a threshold set by decree by the Conseil d’Ét
Slide 79: Resolution 41 - Powers for formalities
Resolution 41 - Powers for formalities The Shareholders, acting in accordance with the quorum and majority requirements applicable to Ordinary General Meetings, grant all powers to the holder of an original copy, an excerpt or a copy of the minutes of this General Meeting certified as authentic, to
Slide 80: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 81: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 82: Proceedings of the Meeting
Proceedings of the Meeting 1. Welcome 2. AGM Preliminary Formalities 3. Introduction 4. Company Overview 5. 2023 Financials 6. Answers to Written Questions 7. Auditor’s Reports 8. Presentation of the Resolutions 9. Discussion 10. Voting 11. Conclusion
Slide 83: Thank you
Thank you Merci Danke Tack valneva